01 September 2018 – The American Food and Drug Administration (FDA)  is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes …

Diabetes: No end to SGLT2-inhibitor drugs side effects Read more »

February 14, 2016 – Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have …

SGLT2 inhibitors and diabetic ketoacidosis: PRAC makes recommendations to minimise risk to patients Read more »

December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors …

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels Read more »

Decreased Bone Density (right panel)

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone …

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy Read more »

May 15, 2015 – The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines Canagliflozin (Invokana), Dapagliflozin (Farxiga), and Empagliflozin (Jardiance) may lead to ketoacidosis, a serious condition where the body produces high levels of …

Medicines based on SGLT2 inhibiton may result in ketoacidosis, a serious condition of too much acid in the blood Read more »

August 1, 2014 – The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes affects approximately 26 million people …

FDA approves Empagliflozin [Jardiance], a SGLT2 inhibitor, to treat type 2 diabetes Read more »